Holen Sie sich die Stockscreener-App
148.18
1.02%
-1.52
Handel nachbörslich:
148.18
Schlusskurs vom Vortag:
$149.70
Offen:
$150.01
24-Stunden-Volumen:
1.98M
Relative Volume:
0.89
Marktkapitalisierung:
$282.75B
Einnahmen:
$54.72B
Nettoeinkommen (Verlust:
$14.02B
KGV:
20.62
EPS:
7.1855
Netto-Cashflow:
$15.32B
1W Leistung:
+1.47%
1M Leistung:
-12.12%
6M Leistung:
+19.84%
1J Leistung:
+33.02%
1-Tages-Spanne:
$147.85
$150.60
1-Wochen-Bereich:
$146.22
$151.78
52-Wochen-Spanne:
$97.72
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
148.18 | 285.65B | 54.72B | 14.02B | 15.32B | 7.1855 |
LLY
Lilly Eli Co
|
878.24 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
119.63 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
AZN
Astrazeneca Plc
|
188.42 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Argus | Hold → Buy |
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2026-01-06 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-12-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-12-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-09-12 | Herabstufung | Goldman | Neutral → Sell |
| 2025-08-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | Herabstufung | UBS | Buy → Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Novartis Bolsters Immunology Pipeline With Excellergy Deal - Zacks Investment Research
Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline - Benzinga
Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy - Proactive financial news
Novartis AG Stock: Strong Analyst Upgrades and Pipeline Momentum Drive Investor Interest in 2026 - AD HOC NEWS
Novartis AG (NVS) Bonds - GuruFocus
Novartis AG stock gains 2% on SIX Swiss Exchange amid strong SMI performance and positive pharma sec - AD HOC NEWS
Novartis AG stock surges on Bank of America price target hike amid strong pharma pipeline momentum - AD HOC NEWS
Novartis AG Stock Faces Pressure Amid Multi-Billion Oncology Acquisition and Pipeline Advances - AD HOC NEWS
NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis AG Stock Gains Traction on Analyst Upgrades and Oncology Pipeline Momentum in 2026 - AD HOC NEWS
Novartis AG stock dips on Swiss Exchange amid $3B breast cancer drug acquisition announcement - AD HOC NEWS
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug - Sahm
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline - ChartMill
NVS Stock Quote Price and Forecast - CNN
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrades and Pipeline Momentum - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Analyst Upgrade and Portfolio Shifts - AD HOC NEWS
Novartis AG Stock (ISIN: CH0012005267) Holds Steady Amid Pharma Sector Shifts - AD HOC NEWS
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa - ChartMill
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income - ChartMill
Novartis slides as shares trade ex-dividend for annual payout - Quiver Quantitative
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Novartis
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy - Novartis
Skeletal Dysplasia Market - GlobeNewswire Inc.
What's Driving the Market Sentiment Around Novartis AG? - Sahm
Novartis Stock: Can New Cancer Bets Keep Beating Big Pharma? - AD HOC NEWS
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas - Finviz
Avidity Biosciences shareholders approve merger with Novartis - Investing.com
Novartis stock hits all-time high at 167.87 USD - Investing.com
Novartis stock hits all-time high at 167.87 USD By Investing.com - Investing.com UK
Novartis India shares surge after Swiss parent agrees $159 mln exit deal - Investing.com
Stocks To Watch, February 20: Swiggy, IT stocks, crude-sensitive stocks, Novartis India, ABB India, CIE Automotive, Zydus Life - Upstox
Where is Novartis AG (NVS) Headed? - Finviz
Nature - Novartis
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals - ChartMill
Itchy Skin Conditions? Novartis' Pivotal Trial Success Shows Potential For Targeted Relief - Sahm
A Look Into Novartis Inc's Price Over Earnings - Sahm
Novartis AG stock reaches all-time high at 160.21 USD - Investing.com Nigeria
Novartis AG stock reaches all-time high at 160.21 USD By Investing.com - Investing.com South Africa
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.74%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):